Cyclosporine-induced autologous graft-versus-host disease following autologous blood stem cell transplantation for lymphoma

Bone Marrow Transplant. 1996 Jun;17(6):1081-3.


Eight consecutive patients with relapsed/refractory non-Hodgkin's lymphoma or Hodgkin's disease received conditioning therapy with BCNU, etoposide, cytosine arabinoside and melphalan (BEAM) followed by autologous blood stem cell transplantation (ABSCT). Cyclosporine was administered from day +1 until day +28 post-ABSCT to induce autologous graft-versus-host disease (GVHD) for a possible antitumor effect. Three patients developed histologically documented grade II GVHD between 22-40 days post-transplant. GVHD resolved with local hydrocortisone 1% application in one patient and after a short course of steroid in the remaining two patients. Further studies are required to document any beneficial antitumor effect of such therapy following ABSCT.

MeSH terms

  • Adult
  • Cyclosporine / pharmacology*
  • Female
  • Graft vs Host Disease / chemically induced*
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Immunosuppressive Agents / pharmacology*
  • Lymphoma / therapy*
  • Male
  • Middle Aged
  • Transplantation, Autologous


  • Immunosuppressive Agents
  • Cyclosporine